PepGen Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 76

Employees

  • Stock Symbol
  • PEPG

Stock Symbol

  • Share Price
  • $1.27
  • (As of Friday Closing)

PepGen General Information

Description

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

Contact Information

Website
www.pepgen.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 321 Harrison Avenue
  • 8th Floor
  • Boston, MA 02118
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Healthcare Technology Systems
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 321 Harrison Avenue
  • 8th Floor
  • Boston, MA 02118
  • United States

PepGen Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PepGen Stock Performance

As of 14-Feb-2025, PepGen’s stock price is $1.27. Its current market cap is $41.4M with 32.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.27 $1.21 $1.16 - $19.30 $41.4M 32.6M 295K -$2.98

PepGen Financials Summary

As of 30-Sep-2024, PepGen has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 136,748 52,827 120,176
Revenue 0 0 0 0
EBITDA (90,021) (84,103) (67,698) (27,081)
Net Income (87,234) (78,626) (69,104) (27,281)
Total Assets 170,234 143,052 217,440 143,641
Total Debt 19,040 20,104 24,534 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PepGen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PepGen‘s full profile, request access.

Request a free trial

PepGen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to tr
Biotechnology
Boston, MA
76 As of 2024

Copenhagen, Denmark
 

Carmel, IN
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PepGen Competitors (66)

One of PepGen’s 66 competitors is Antag Therapeutics, a Venture Capital-Backed company based in Copenhagen, Denmark.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Antag Therapeutics Venture Capital-Backed Copenhagen, Denmark
MBX Biosciences Formerly VC-backed Carmel, IN
Alzheon Venture Capital-Backed Framingham, MA
Sorrento Therapeutics Formerly VC-backed San Diego, CA
Apeptico Venture Capital-Backed Vienna, Austria
You’re viewing 5 of 66 competitors. Get the full list »

PepGen Patents

PepGen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3212994-A1 Methods of treating myotonic dystrophy type 1 using peptide-oligonucleotide conjugates Pending 12-Mar-2021
EP-4304628-A2 Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates Pending 12-Mar-2021
EP-4304657-A2 Methods of treating myotonic dystrophy type 1 using peptide-oligonucleotide conjugates Pending 12-Mar-2021
US-20240189434-A1 Methods of treating myotonic dystrophy type 1 using peptide-oligonucleotide conjugates Pending 12-Mar-2021
US-20240200062-A1 Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates Pending 12-Mar-2021 C12N15/113
To view PepGen’s complete patent history, request access »

PepGen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PepGen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore PepGen‘s full profile, request access.

Request a free trial

PepGen ESG

Risk Overview

Risk Rating

Updated May, 09, 2023

29.92 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Biotechnology

Subindustry

of 368

Rank

Percentile

To view PepGen’s complete esg history, request access »

PepGen FAQs

  • When was PepGen founded?

    PepGen was founded in 2018.

  • Where is PepGen headquartered?

    PepGen is headquartered in Boston, MA.

  • What is the size of PepGen?

    PepGen has 76 total employees.

  • What industry is PepGen in?

    PepGen’s primary industry is Biotechnology.

  • Is PepGen a private or public company?

    PepGen is a Public company.

  • What is PepGen’s stock symbol?

    The ticker symbol for PepGen is PEPG.

  • What is the current stock price of PepGen?

    As of 14-Feb-2025 the stock price of PepGen is $1.27.

  • What is the current market cap of PepGen?

    The current market capitalization of PepGen is $41.4M.

  • Who are PepGen’s competitors?

    Antag Therapeutics, MBX Biosciences, Alzheon, Sorrento Therapeutics, and Apeptico are some of the 66 competitors of PepGen.

  • What is PepGen’s annual earnings per share (EPS)?

    PepGen’s EPS for 12 months was -$2.98.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »